Science Translational Medicine
03 February 2021 Vol 13, Issue 579
Development and deployment of COVID-19 vaccines for those most vulnerable
By Wayne C. Koff, Theodore Schenkelberg, Tere Williams, Ralph S. Baric, Adrian McDermott, Cheryl M. Cameron, Mark J. Cameron, Matthew B. Friemann, Gabriele Neumann, Yoshihiro Kawaoka, Alyson A. Kelvin, Ted M. Ross, Stacey Schultz-Cherry, Timothy D. Mastro, Frances H. Priddy, Kristine A. Moore, Julia T. Ostrowsky, Michael T. Osterholm, Jaap Goudsmit
Science Translational Medicine03 Feb 2021 Full Access
Ensuring that COVID-19 vaccines are delivered to older populations and those living in low resource settings is essential to end the pandemic.
Development of safe and effective COVID-19 vaccines is a global priority and the best hope for ending the COVID-19 pandemic. Remarkably, in less than 1 year, vaccines have been developed and shown to be efficacious and are already being deployed worldwide. Yet, many challenges remain. Immune senescence and comorbidities in aging populations and immune dysregulation in populations living in low-resource settings may impede vaccine effectiveness. Distribution of vaccines among these populations where vaccine access is historically low remains challenging. In this Review, we address these challenges and provide strategies for ensuring that vaccines are developed and deployed for those most vulnerable.